首页> 外文学位 >Crystallization in pharmaceutical materials: I. Cross-nucleation between polymorphs. II. Solubility of crystalline drugs in polymers.
【24h】

Crystallization in pharmaceutical materials: I. Cross-nucleation between polymorphs. II. Solubility of crystalline drugs in polymers.

机译:药物材料中的结晶:I.多晶型物之间的交叉成核。二。结晶药物在聚合物中的溶解度。

获取原文
获取原文并翻译 | 示例

摘要

This thesis work studied two problems in the crystallization of pharmaceutical substances: (i) cross-nucleation between polymorphs and (ii) solubility of crystalline drugs in polymers. Cross-nucleation between polymorphs is the nucleation of a new polymorph on an existing and growing polymorph. It is important to the control of polymorphism and to the basic understanding of crystal nucleation. This phenomenon has been studied in D-mannitol (sometimes containing polyvinylpyrrolidone to slow down crystallization) in spontaneous and seeded crystallization. The polymorphic outcome of a seeded crystallization depends on the seed polymorph, temperature, relative growth rates of polymorphs, and the crystallographic orientation of the seeds. The cross-nucleation process observed in spontaneous crystallization follows Poisson statistics. The dependence of the cross-nucleation rate on liquid thickness shows that the process occurs at the growth front of the initial polymorph, unaffected by container surfaces.;The solubility of crystalline drugs in polymers defines the maximal drug loading without the risk of crystallization and indicates the driving force for an amorphous drug to crystallize from its solid dispersion in a polymer matrix. This property is difficult to measure because the high viscosity of polymers makes achieving solubility equilibrium difficult. Two methods based on Differential Scanning Calorimetry (DSC) have been developed for measuring this property. The scanning method detects the dissolution endpoint of an intimate mixture of drug/polymer during slow heating. The scanning method holds a drug/polymer mixture for effectively as long as possible near the dissolution endpoint to ensure phase equilibrium and rescans the mixture to detect any undissolved crystals. The annealing method increases the likelihood of achieving phase equilibria and extends the temperature range of measurement closer to Tg. The methods were used to obtain, for the first time, the solubilities of crystalline D-mannitol, indomethacin, and nifedipine in polymers near the glass transition temperature. The solubilities have been compared in polymers of different structures, molecular weights, and hydrophilicity. The methods have the potential of providing useful data for designing physically stable formulations of amorphous drugs.
机译:本文的工作研究了药物结晶过程中的两个问题:(i)多晶型物之间的交叉成核和(ii)结晶药物在聚合物中的溶解度。多晶型物之间的交叉成核是新的多晶型物在现有且正在增长的多晶型物上的成核。这对于控制多态性和对晶体成核的基本理解很重要。在D-甘露醇(有时含有聚乙烯吡咯烷酮以减缓结晶)中自发和晶种结晶中已研究了这种现象。晶种的多晶型结果取决于晶种,晶型温度,晶型的相对生长速率以及晶型。自发结晶中观察到的交叉成核过程遵循泊松统计。交叉成核速率对液体厚度的依赖性表明,该过程发生在初始多晶型物的生长前沿,不受容器表面的影响。结晶药物在聚合物中的溶解度定义了最大的药物载量而没有结晶的危险并表明无定形药物从其在聚合物基质中的固体分散体结晶的驱动力。由于聚合物的高粘度使得难以实现溶解度平衡,因此难以测量该性质。已经开发了两种基于差示扫描量热法(DSC)的方法来测量该性质。扫描方法可检测缓慢加热过程中药物/聚合物紧密混合物的溶解终点。扫描方法将药物/聚合物混合物在溶解终点附近保持尽可能长的时间,以确保相平衡,然后重新扫描混合物以检测任何未溶解的晶体。退火方法增加了达到相平衡的可能性,并将测量温度范围扩展到更接近Tg。该方法首次用于获得玻璃化转变温度附近的结晶D-甘露糖醇,消炎痛和硝苯地平在聚合物中的溶解度。已经比较了在不同结构,分子量和亲水性的聚合物中的溶解度。该方法具有为设计无定形药物的物理稳定制剂提供有用数据的潜力。

著录项

  • 作者

    Tao, Jing.;

  • 作者单位

    The University of Wisconsin - Madison.;

  • 授予单位 The University of Wisconsin - Madison.;
  • 学科 Health Sciences Pharmacology.
  • 学位 Ph.D.
  • 年度 2009
  • 页码 133 p.
  • 总页数 133
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号